Claims for Patent: 10,849,919

✉ Email this page to a colleague

Summary for Patent: 10,849,919

Title:	Cladribine regimen for treating progressive forms of multiple sclerosis
Abstract:	Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine.
Inventor(s):	Dangond Fernando, Dotzauer Matthias
Assignee:	Merck Patent GmbH
Application Number:	US16199119
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,849,919
Patent Claims:

Details for Patent 10,849,919

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	July 23, 1993	10,849,919	2038-11-23
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	May 17, 1996	10,849,919	2038-11-23
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	May 28, 2003	10,849,919	2038-11-23
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	February 27, 2012	10,849,919	2038-11-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.